| Literature DB >> 17955443 |
Mohammad Rashel1, Jumpei Uchiyama, Takako Ujihara, Yoshio Uehara, Shu Kuramoto, Shigeyoshi Sugihara, Ken-Ichi Yagyu, Asako Muraoka, Motoyuki Sugai, Keiichi Hiramatsu, Koichi Honke, Shigenobu Matsuzaki.
Abstract
We report the successful purification of a cloned lysin encoded by the novel Staphylococcus aureus bacteriophage phi MR11. The lysin, designated MV-L, rapidly and completely lysed cells of a number of S. aureus strains tested, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant S. aureus and a subset of vancomycin-intermediate S. aureus (VISA) in growing conditions. MV-L-mediated killing is specific to S. aureus and not to other species, except for S. simulans. MV-L exerted its staphylocidal effect synergistically with glycopeptide antibiotics against VISA. MV-L efficiently eliminated MRSA that had been artificially inoculated into the nares of mice. The intraperitoneal administration of MV-L also protected mice against MRSA septic death, without any harmful effects. Although MV-L evoked detectable levels of a humoral response in mice, the antibodies did not abolish the bacteriolytic activity. These results indicate that MV-L might be useful as a powerful therapeutic agent against multidrug-resistant S. aureus infections.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17955443 DOI: 10.1086/521305
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226